{"id":"https://openalex.org/W4413050737","doi":null,"title":"Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients.","display_name":"Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients.","publication_year":2025,"publication_date":"2025-08-01","ids":{"openalex":"https://openalex.org/W4413050737","pmid":"https://pubmed.ncbi.nlm.nih.gov/40773600"},"language":"en","primary_location":{"id":"pmid:40773600","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40773600","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of drugs in dermatology : JDD","raw_type":"Journal Article"},"volume":null,"type":"article","indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091485944","display_name":"Bruce E Strober","orcid":"https://orcid.org/0000-0002-8394-2057","observed_orcids":["https://orcid.org/0000-0002-8394-2057"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruce E Strober","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057675915","display_name":"Jud C. Janak","orcid":"https://orcid.org/0009-0001-5620-5211","observed_orcids":["https://orcid.org/0009-0001-5620-5211"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jud C Janak","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033613047","display_name":"Timothy P. Fitzgerald","orcid":"https://orcid.org/0000-0003-3441-1708","observed_orcids":["https://orcid.org/0000-0003-3441-1708"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Timothy Fitzgerald","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091838080","display_name":"Maya Marchese","orcid":"https://orcid.org/0000-0003-1915-5793","observed_orcids":["https://orcid.org/0000-0003-1915-5793"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maya Marchese","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022209631","display_name":"Rachel E. Teneralli","orcid":"https://orcid.org/0000-0003-4340-9001","observed_orcids":["https://orcid.org/0000-0003-4340-9001"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rachel E Teneralli","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014696794","display_name":"Katelyn Rowland","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katelyn Rowland","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016368189","display_name":"Olivia Choi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Olivia Choi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036727307","display_name":"Daphne Chan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daphne Chan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Elizabeth Lesser","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elizabeth Lesser","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037717245","display_name":"Michael C. Cameron","orcid":"https://orcid.org/0000-0002-0622-2312","observed_orcids":["https://orcid.org/0000-0002-0622-2312"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Cameron","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5038505651","display_name":"Mark Lebwohl","orcid":"https://orcid.org/0000-0002-4705-5303","observed_orcids":["https://orcid.org/0000-0002-4705-5303"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Lebwohl","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.14834724,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"24","issue":"8","first_page":"762","last_page":"768"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/plaque-psoriasis","display_name":"plaque psoriasis","score":0.9620000123977661},{"id":"https://openalex.org/keywords/medication-persistence","display_name":"treatment persistence","score":0.9309999942779541},{"id":"https://openalex.org/keywords/biologic-naive-patients","display_name":"biologic-naive patients","score":0.8209999799728394},{"id":"https://openalex.org/keywords/biologic-experienced-patients","display_name":"biologic-experienced patients","score":0.9829999804496765},{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/secukinumab","display_name":"secukinumab","score":1.0},{"id":"https://openalex.org/keywords/ixekizumab","display_name":"ixekizumab","score":1.0},{"id":"https://openalex.org/keywords/restricted-mean-survival-time","display_name":"restricted mean survival time","score":0.7369999885559082},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.43700000643730164},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.3959999978542328}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.984463632106781},{"id":"https://openalex.org/C3020604521","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Plaque psoriasis","level":3,"score":0.8904823064804077},{"id":"https://openalex.org/C2781009140","wikidata":"https://www.wikidata.org/wiki/Q7170389","display_name":"Persistence (discontinuity)","level":2,"score":0.8286596536636353},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.6531690359115601},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.6432933807373047},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34016233682632446},{"id":"https://openalex.org/C187320778","wikidata":"https://www.wikidata.org/wiki/Q1349130","display_name":"Geotechnical engineering","level":1,"score":0.0},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000068879","descriptor_name":"Adalimumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000068879","descriptor_name":"Adalimumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000068879","descriptor_name":"Adalimumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000068879","descriptor_name":"Adalimumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001688","descriptor_name":"Biological Products","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001688","descriptor_name":"Biological Products","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001688","descriptor_name":"Biological Products","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001688","descriptor_name":"Biological Products","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012042","descriptor_name":"Registries","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D012042","descriptor_name":"Registries","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":1,"locations":[{"id":"pmid:40773600","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40773600","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of drugs in dermatology : JDD","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"sustainable_development_goals_aurora":[],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4210767205","https://openalex.org/W2418145303","https://openalex.org/W2391784904","https://openalex.org/W2347638186","https://openalex.org/W4381512312","https://openalex.org/W1986850072","https://openalex.org/W4237828778","https://openalex.org/W2331246794","https://openalex.org/W4388415171","https://openalex.org/W4387014929"],"abstract_inverted_index":{"OBJECTIVE:":[0],"The":[1,52,130,192],"study":[2],"objective":[3],"was":[4,56,79,104,135,166,197,233],"to":[5,81,239,247],"compare":[6],"long-term":[7],"treatment":[8,59,91,100,162,231],"persistence":[9,101,163,232],"between":[10],"patients":[11,27],"initiating":[12,34],"guselkumab":[13,69,103,134,165,196,237],"vs":[14,142,148,155,204,210,217],"3":[15],"commonly":[16],"prescribed":[17],"biologics":[18],"in":[19,29,226],"the":[20,30,98,160],"United":[21],"States.":[22],"METHODS:":[23],"Adult":[24],"plaque":[25],"psoriasis":[26],"enrolled":[28],"CorEvitas":[31],"Psoriasis":[32],"Registry":[33],"guselkumab,":[35],"adalimumab,":[36,71,143,178,205],"secukinumab,":[37,72,122,184],"or":[38],"ixekizumab":[39],"(July":[40],"2017":[41],"-":[42],"January":[43],"2022)":[44],"were":[45,93],"divided":[46],"into":[47],"biologic-na\u00efve":[48,87,96,222],"and":[49,73,88,123,150,185,212,223,241,243],"biologic-experienced":[50,90,158,224],"cohorts.":[51],"primary":[53],"outcome":[54],"measure":[55],"average":[57,230],"2-year":[58],"persistence,":[60],"estimated":[61],"as":[62],"restricted":[63],"mean":[64],"survival":[65],"time":[66],"(RMST),":[67],"comparing":[68],"with":[70],"ixekizumab.":[74,129,156,191,218,248],"Standardized":[75],"mortality":[76],"ratio":[77],"weighting":[78],"used":[80],"adjust":[82],"for":[83,102,115,121,128,133,164,177,183,190,195,236],"confounding.":[84],"RESULTS:":[85],"1,007":[86],"1,584":[89],"initiations":[92],"included.":[94],"For":[95,157],"initiators,":[97,159],"weighted-average":[99,161],"20.3":[105],"months":[106,112,118,125,168,174,180,187],"(95%":[107,138,169,200],"CI:":[108,139,170,201],"19.4,":[109],"21.3),":[110],"14.6":[111],"(13.5,":[113],"15.7)":[114],"adalimumab;":[116],"17.5":[117],"(16.5,":[119],"18.6)":[120],"18.9":[124],"(17.8,":[126],"20.1)":[127],"RMST":[131,193],"difference":[132,194],"24.9":[136],"weeks":[137,145,152,199,207,214],"18.4,":[140],"31.3)":[141],"12.1":[144],"(5.9,":[146],"18.2)":[147],"secukinumab":[149,211,242],"6.0":[151],"(0.4,":[153],"12.4)":[154],"17.6":[167],"16.9,":[171],"18.4),":[172],"13.5":[173],"(11.6,":[175],"15.5)":[176],"16.5":[179],"(15.7,":[181],"17.3)":[182],"16.9":[186],"(16.1,":[188],"17.8)":[189],"17.7":[198],"8.7,":[202],"26.7)":[203],"5.0":[206],"(0.2,":[208],"9.1)":[209],"2.9":[213],"(-1.9,":[215],"7.7)":[216],"CONCLUSIONS:":[219],"In":[220],"both":[221],"cohorts":[225],"this":[227],"real-world":[228],"study,":[229],"significantly":[234],"longer":[235,245],"compared":[238,246],"adalimumab":[240],"numerically":[244]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-10T00:00:00"}